RiverVest Venture Fund IV, L.P.
Known title: 10% OwnerCIK: 0001725443
RiverVest Venture Fund IV, L.P.'s purchase track record
RiverVest Venture Fund IV, L.P. has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 10/26/2021 | XLO | $4.00M | -13.7% | -77.3% | -8.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| XLO | ▲ Buy | Open Market | 250,000 | $4.0M | 10/26/2021 | View on chart |
| XLO | ▼ Sell | Other | 832,120 | — | 10/26/2021 | View on chart |
| XLO | ▼ Sell | Other | 359,324 | — | 10/26/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Xilio Therapeutics appoints Yariv J. Houvras as Chief Medical Officer
Xilio Therapeutics announced that Dr. Yariv J. Houvras, M.D., Ph.D., will serve as its new Chief Medical Officer. The appointment adds experienced clinical leadership to the company as it advances its therapeutic pipeline. This change comes while the stock is trading near the top of its 52‑week range, suggesting market attention to the leadership update.
Xilio Therapeutics appoints Yariv J. Houvras as Chief Medical Officer. Xilio Therapeutics announced that Dr. Yariv J. Houvras, M.D., Ph.D., will serve as its new Chief Medical Officer. The appointment adds experienced clinical leadership to the company as it advances its therapeutic pipeline. This change comes while the stock is trading near the top of its 52‑week range, suggesting market attention to the leadership update.